Welcome to our dedicated page for ORGANON & news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & stock.
Organon & Co. reports developments as a global healthcare company with portfolios in Women's Health and General Medicines, including biosimilars. Company news commonly covers operating results, product and regulatory updates, and clinical data for medicines such as VTAMA cream for atopic dermatitis and plaque psoriasis, biosimilar approvals including POHERDY, and established women's health brands and devices such as Nexplanon, Follistim, and Jada.
Updates also address capital-structure disclosures, governance matters, shareholder voting topics, and material agreements, alongside the company's commercial activity across more than 140 markets.
Organon (NYSE: OGN) and Henlius announced the Canadian launch of BILDYOS 60 mg/1 mL and TUZEMTY 120 mg/1.7 mL, denosumab biosimilars to PROLIA and XGEVA, for all reference indications.
The launch expands Organon Canada’s biosimilars portfolio to eight products across five therapeutic areas, supporting broader access to cost-effective osteoporosis and oncology bone-care treatments.
Organon (NYSE: OGN) completed a global licensing agreement with Sebela Pharmaceuticals for exclusive rights to MIUDELLA, a hormone-free copper IUD. The FDA-approved device prevents pregnancy for up to three years, is 99% effective, and uses proprietary SLIMSERT technology. US commercial launch is anticipated in late 2026 under a REMS program.
Organon (NYSE:OGN) and Samsung Bioepis expanded their agreement, giving Organon exclusive rights to commercialize PYZCHIVA (ustekinumab), a biosimilar referencing STELARA, in Canada.
This amendment grows their Canadian biosimilar portfolio from five to six products, with PYZCHIVA expected to launch in 2026 across multiple immunology and dermatology indications.
Summary not available.
Organon (NYSE:OGN) will present eight new health economics and outcomes research abstracts at ISPOR 2026, held May 17-20, 2026 in Philadelphia.
Presentations cover contraception affordability, biosimilar adoption, VTAMA budget impact, and headache referral patterns across women’s health, dermatology, biosimilars, and neurology.
Organon (NYSE: OGN) reported Q1 2026 results: $1.460 billion revenue (down 4% as-reported; down 9% ex-FX), GAAP net income of $146 million and diluted EPS of $0.55. Adjusted EBITDA was $415 million (28.4% margin). The company announced a pending all-cash merger into Sun Pharma expected to close in early 2027, and suspended guidance and earnings calls while the transaction is pending.
Organon (NYSE: OGN) canceled its first quarter 2026 earnings conference call scheduled for May 7, 2026 after announcing on April 26, 2026 that it entered into an agreement for Sun Pharmaceutical Industries Limited to acquire Organon. Organon will release Q1 2026 results on April 30, 2026 and file a Form 10-Q with the SEC.
Organon (NYSE: OGN) and Henlius announced the European Commission approval of POHERDY® (pertuzumab) on April 29, 2026, the first approved biosimilar to PERJETA in Europe for all reference-product indications.
POHERDY is indicated in combination with trastuzumab and chemotherapy for neoadjuvant, adjuvant, and metastatic HER2‑positive breast cancer. Organon holds exclusive global commercialization rights outside China under a 2022 license agreement with Henlius.
Sun Pharma (NYSE:—) to acquire Organon (NYSE:OGN) for US$14.00 per share in an all-cash deal valuing Organon at US$11.75 billion enterprise value. Transaction expected to close in early 2027, subject to regulatory approvals and Organon stockholder vote. Combined revenue projected at US$12.4 billion.
Organon reported 2025 revenue US$6.2B, Adjusted EBITDA US$1.9B, debt US$8.6B and cash US$574M. Sun Pharma expects Net Debt/EBITDA ~2.3x post-transaction.
Organon (NYSE: OGN) will release its first quarter 2026 financial results on May 7, 2026 and will host a webcast and conference call at 8:30 a.m. ET.
The company said it does not currently expect to record any milestone expense in Q1 2026, but results are preliminary and subject to closing procedures. The live webcast and a replay (available ~two hours after the call) can be accessed on the company website; dial-in details and Conference ID are provided for analysts and investors.